Lakefront Biotherapeutics (LKFT) Change in Working Capital (2018 - 2026)

Lakefront Biotherapeutics (LKFT) has 9 years of Change in Working Capital data on file, last reported at -$14.4 million in Q1 2026.

• Change in Working Capital for Q1 2026 came in at -$14.4 million, up 1.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$70.5 million (up 23.52% YoY), and the FY2020 annual result was $4.8 million, up 156.67% from the prior year.
• Change in Working Capital rose to -$14.4 million in Q1 2026 per LKFT's latest filing, from -$31.5 million in the prior quarter.
• Over five years, Change in Working Capital peaked at $3.5 million in Q1 2022 and troughed at -$31.5 million in Q3 2025.
• A 5-year average of -$17.3 million and a median of -$14.5 million in 2025 frame the typical range for Change in Working Capital.
• The sharpest annual moves came in 2022 and 2023: Change in Working Capital soared 267.13% in 2022, then slumped 405.17% in 2023.
• A 5-year view of Change in Working Capital shows it stood at $3.5 million in 2022, then tumbled by 405.17% to -$10.7 million in 2023, then sank by 122.77% to -$23.8 million in 2024, then slumped by 32.3% to -$31.5 million in 2025, then jumped by 54.47% to -$14.4 million in 2026.
• Business Quant data shows LKFT's Change in Working Capital at -$14.4 million in Q1 2026, -$31.5 million in Q3 2025, and -$10.1 million in Q2 2025.